Next Article in Journal
Thrombelastography and Conventional Coagulation Markers in Chronic Obstructive Pulmonary Disease: A Prospective Paired-Measurements Study Comparing Exacerbation and Stable Phases
Next Article in Special Issue
IL-10 Enhances the Inhibitory Effect of Adipose-Derived Stromal Cells on Insulin Resistance/Liver Gluconeogenesis by Treg Cell Induction
Previous Article in Journal
Correction: Han et al. MicroRNA-146b-5p Suppresses Pro-Inflammatory Mediator Synthesis via Targeting TRAF6, IRAK1, and RELA in Lipopolysaccharide-Stimulated Human Dental Pulp Cells. Int. J. Mol. Sci. 2023, 24, 7433
Previous Article in Special Issue
Chemerin as an Inducer of β Cell Proliferation Mediates Mitochondrial Homeostasis and Promotes β Cell Mass Expansion
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 4
10.3390/ijms25042050
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity

by
Karla MacDonald-Ramos
1,2,*,
Adriana Monroy
3,
Mariana Bobadilla-Bravo
2 and
Marco Cerbón
2,*
1
Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico
2
Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico
3
Servicio de Oncología, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México 06720, Mexico
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(4), 2050; https://doi.org/10.3390/ijms25042050
Submission received: 31 December 2023 / Revised: 25 January 2024 / Accepted: 26 January 2024 / Published: 8 February 2024
(This article belongs to the Special Issue Mechanisms of Insulin Resistance and Adipose Tissue Dysfunction 2.0)
Review Reports Versions Notes

Abstract

:
Silymarin has ameliorated obesity, type 2 diabetes (T2DM), and insulin resistance (IR) in combination with standard therapy, diet, or exercise in recent studies. Obesity and IR are the main risk factors for developing T2DM and other metabolic disorders. Today, there is a need for new strategies to target IR in patients with these metabolic diseases. In the present longitudinal study, a group of non-diabetic insulin-resistant women with type 1 and type 2 obesity were given silymarin for 12 weeks, with no change in habitual diet and physical activity. We used the Homeostatic Model Assessment for Insulin Resistance Index (HOMA-IR) to determine IR at baseline and after silymarin treatment (t = 12 weeks). We obtained five timepoint oral glucose tolerance tests, and other biochemical and clinical parameters were analyzed before and after treatment. Treatment with silymarin alone significantly reduced mean fasting plasma glucose (FPG) and HOMA-IR levels at 12 weeks compared to baseline values (p < 0.05). Mean fasting plasma insulin (FPI), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (Tg), indirect bilirubin, and C-reactive protein (CRP) levels decreased compared to baseline values, although changes were non-significant. The overall results suggest that silymarin may offer a therapeutic alternative to improve IR in non-diabetic individuals with obesity. Further clinical trials are needed in this type of patient to strengthen the results of this study.

1. Introduction

Each year, around 2.8 million individuals worldwide die from causes associated with overweight or obesity [1,2,3]. Obesity is the excess or abnormal accumulation of adipose tissue (AT) in the body, which is harmful to health and linked to the development of metabolic disorders, among others [4,5,6,7]. Obesity is also a systemic and multifactorial disease and is considered an inflammatory, chronic, and low-grade systemic process, mainly due to the infiltration of macrophages that permeate AT, modulate inflammation, and are the principal source of proinflammatory cytokines. As proinflammatory cytokines interfere with insulin signaling pathways, the inflammatory state generated in obesity is a central factor in developing insulin resistance (IR) [5,6,7,8,9,10]. Specific medications for glycemic control can optimize insulin response and reduce insulin demand. These include metformin, glucagon-like peptide inhibitors, sodium-glucose cotransporters-2, dipeptidyl peptidase-4 cotransporters, and thiazolidinediones. Regardless of drug treatment, when IR is chronic, it can progress to the development of metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and type 2 diabetes (T2DM) [11,12,13,14].
Other strategies employed in treating metabolic diseases include natural extracts, such as silymarin [15,16,17], combined with standard treatment for metabolic disease in several studies [18,19,20,21,22,23,24,25,26,27]. Silymarin contains six flavonolignans, primarily silybin A and B, obtained through extraction [18,19,20,28]. The beneficial effects of silymarin on human health, including its antioxidant, anti-inflammatory, antiviral, cytoprotective, and anticarcinogenic effects, have been studied [21,22,23,25,26,29,30]. Notably, silymarin has ameliorated liver disease, as shown in in vitro and animal studies [31,32,33,34,35,36,37,38,39,40,41,42,43,44] and in humans [45,46,47,48]. Researchers have developed different pharmacological formulations of silymarin due to its low bioavailability in its natural state; new biotechnologies, including nanotechnologies, have solved this problem [28,49,50,51,52].
Interestingly, recent studies have used silymarin to help treat individuals with metabolic disease and IR. Many authors have reported the effects of silymarin administration on IR in several diabetes, obesity, and NAFLD animal study models and in vitro study models. In addition to an overall reduction in IR, silymarin treatment also reduced weight and epididymal fat mass, improved endothelial dysfunction, decreased oxidative stress indicators, such as nuclear factor kappa-light-chain-enhancer of activated B cell (NF-kB expression and tumor necrosis factor-alpha (TNF-α) levels, and restored, or prevented the inhibition of, the insulin receptor substrate 1(IRS-1)/phosphatidylinositol-3 kinase (P13K)/protein kinase B (Akt) pathway, and others [42,43,53,54,55,56,57,58,59,60,61]. In clinical studies, silymarin combined with standard treatment and other natural compounds, such as berberine and vitamins, improved IR, lipid metabolism, or inflammatory markers in T2DM, alone or with comorbidities, such as hepatic cirrhosis, chronic liver diseases, obesity, or dyslipidemia [44,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83]. Recently, a detailed meta-analysis of the metabolic effect of the association of silymarin and berberine in clinical trials found that the coadministration of these nutraceuticals improved lipid and glucose profiles and may promote cardiometabolic health. Other recent clinical studies with silymarin and novel nutraceutical supplements improved biomarkers associated with obesity, or lipid metabolism, but not IR [84,85,86].
These studies show that silymarin administration improved various parameters associated with obesity and T2DM. However, it is unknown whether silymarin treatment alone decreases IR in non-diabetic individuals with obesity. This study aimed to establish whether silymarin treatment alone ameliorated IR in obese individuals without T2DM.

2. Results

After 12 weeks of silymarin treatment, we observed no significant differences in body composition parameters in the patients in the patients. We show the clinical, anthropometric, and body composition characteristics of the enrolled patients in Table 1.
We observed a reduction in almost all biochemical parameters after treatment was completed compared to baseline values (Table 2). Mean fasting plasma glucose (FPG) and Homeostatic Model Assessment for Insulin Resistance Index (HOMA-IR) levels decreased significantly after silymarin treatment (t = 12 weeks) (Supplemental Figure S1). Mean fasting plasma insulin (FPI), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides (Tg), indirect bilirubin, and C-reactive protein (CRP) levels decreased after 12 weeks of silymarin treatment, although these differences were non-significant.
In the oral glucose tolerance test (OGTT), we observed a significant decrease in mean FPG levels after silymarin treatment (t = 12 weeks) compared to baseline values. Additionally, mean glucose levels at 30, 60, 90, and 120 min, and insulin levels at 0, 30, 60, and 120 min, decreased after silymarin treatment (t = 12 weeks) compared to baseline values, although the change was non-significant. Interestingly, mean insulin levels increased at 90 min in the OGTT after silymarin treatment (t = 12 weeks) compared to mean baseline insulin values (Table 3). We show the differences in mean glucose and insulin levels in patients during the OGTT, at baseline, and after silymarin treatment (t = 12 weeks) in Table 3.
The glucose response curves at baseline and after silymarin treatment (t = 12 weeks) were monophasic and followed a similar pattern [87,88], displaying maximum mean glucose values at 60 min. Mean glucose baseline values two hours post-glucose load during the OGTT indicated prediabetes. However, mean glucose values after silymarin treatment (t = 12 weeks) two hours post-glucose load during the OGTT indicated normoglycemia (Supplemental Figure S2a) [89,90,91,92]. By contrast, the insulin clearance curves at baseline and after silymarin treatment (t = 12 weeks) did not follow a similar pattern. The baseline insulin clearance curve was biphasic [87,88]; mean insulin levels increased until 60 min, then decreased until 90 min, and increased again with maximum values at 120 min. After 12 weeks of silymarin treatment, the insulin clearance curve was monophasic [87,88]; mean insulin values gradually increased until 90 min, reached maximum values, and decreased slightly until 120 min (Supplemental Figure S2b). We show the glucose response and insulin clearance curves during the OGTT, at baseline, and after silymarin treatment (t = 12 weeks) in Supplemental Figure S2.

3. Discussion

One of the aims of this study was to analyze the effect of silymarin treatment alone on IR in obese individuals without T2DM. The silymarin formulation used in this study improved IR significantly in the group of non-diabetic women with obesity after twelve weeks of treatment. Primarily, the results showed that silymarin administration reduced mean glucose and HOMA-IR levels significantly, as in other clinical trials that analyzed the effect of silymarin treatment in insulin-resistant individuals [62,63,65,66,67,68,69,70,71,72,75,76,80,81,82,93]. A significant reduction in mean glucose levels in our study suggests that silymarin treatment increased insulin sensitivity in target tissues, thereby promoting the expression of the glucose receptor and the entry of glucose into cells. In addition, we observed this reduction employing a lower dose of silymarin and with a shorter duration of treatment than in other studies that reported a decrease in glucose levels [48,62,65,70,71,72,79,93] or in others that reported a decreased IR [64,65,66,67,68,69,73,74,76,80,81,82,83,93].
The results of our study are in line with the results of other studies that also reported a decrease in IR in diabetic individuals with silymarin administration as an adjunct to standard insulin therapy for T2DM [65,67,69] or in diabetic individuals with cirrhosis [62,63]. Other studies that reported a decrease in IR employed silymarin combined with B. aristata to treat patients with T2DM simultaneously with insulin/metformin/incretins/sulfonylureas/glitazones [66] or without standard treatment for T2DM but with a hypocaloric diet and physical activity [68]. Other authors that reported a decrease in IR conducted studies in individuals with NAFLD, with or without hepatitis C virus (HCV), but all with silymarin combined with vitamin (Vit) E [70,71,72,74], Vit E and the Mediterranean diet or lifestyle modifications [75,76], or with Vit D [79,93]. Our study’s population most closely resembled those in three studies conducted in groups of dyslipidemic overweight individuals, where two of the three studies reported a decrease in IR [81,82,83,94]. However, treatment with silymarin in these studies was in combination with B. aristata, in addition to the prescription of physical activity, a hypocaloric diet, or a reduced dose of statins. In our study, we did not use silymarin combined with other nutraceuticals or prescribe a change in diet or physical activity to analyze the effects of silymarin alone on IR, thus avoiding the presence of confounding factors in the results of our study. To the best of our knowledge, the present study is the first to use and report that treatment with silymarin alone significantly reduced IR in a group of IR non-diabetic obese women without dietary therapy or physical activity after only 12 weeks of treatment.
Although mean baseline FPG levels in our population decreased significantly after silymarin treatment (t = 12 weeks) (96.7 ± 4.2 mg/dL vs. 91.2 ± 6.8 mg/dL, p = 0.041), the values were within a normoglycemic range [89,90,91,92]. However, mean baseline glucose levels at two hours post-glucose load during the OGTT (147.0 ± 21.5 mg/dL) indicated that our study population was prediabetic [89,90,91,92]. After 12 weeks of silymarin treatment, mean glucose levels at two hours post-glucose load during the OGTT (138.6 ± 26.3 mg/dL) were within normoglycemic values. This change suggests that silymarin treatment may have decreased the risk or delayed development of T2DM in our study population by modifying an initial state of prediabetes to normoglycemia [89,90,91,92]. Additionally, the shape of the glucose response curve during the OGTT at baseline and after silymarin treatment (t = 12 weeks) in the results was monophasic. Several studies have reported a monophasic glucose response curve in individuals who have lower insulin sensitivity, decreased β-pancreatic cell function, and may be at an increased risk of developing impaired FPG or T2DM [87,88,95,96,97,98]. This evidence suggests that our study population may share these characteristics since HOMA-IR, used to measure IR in our study, is a simple surrogate index for insulin sensitivity [99,100]. Alternatively, in the results, the shape of the insulin clearance curve during the OGTT at baseline was biphasic, and after silymarin treatment (t = 12 weeks) was monophasic. Several studies have reported both types of insulin clearance curves in individuals with decreased insulin sensitivity [87,88,95,96,97,98]. This evidence further supports that our study population had reduced sensitivity to insulin at baseline.
A decrease in mean FPI levels after silymarin treatment (t = 12 weeks) compared to baseline values was observed, as in other studies [62,63,66,67], although the change was non-significant. A reduction in FPI levels suggests that the demand for insulin production decreased and tissue sensitivity to insulin increased [11]. The absence of a significant decrease in mean FPI levels after silymarin treatment (t = 12 weeks) may be due to the small sample size and duration of silymarin treatment in our study. Additionally, we observed a reduction in mean CT, LDL-C, Tg, BI, and CRP levels, as reported by others, although without significant changes [64,65,66,67,68,69,73,74,76,80,81,82,83,93]. Yet, mean Tg baseline levels in our study population (154.8 ± 47.6 mg/dL) indicated the presence of hypertriglyceridemia [101]. After 12 weeks of silymarin treatment, mean Tg levels (145.0 ± 43.5 mg/dL) no longer displayed hypertriglyceridemia. Therefore, although the decrease was non-significant, hypertriglyceridemia was eliminated in the patients after 12 weeks of treatment with silymarin. Alternatively, we did not observe changes in body composition in our study population after treatment with silymarin. Other studies with silymarin treatment reported a decrease in body mass index (BMI) and body fat [68,70,72,76,77], although the authors prescribed silymarin in combination with physical activity and dietary therapy or with a longer duration of treatment than in the present study. The absence of observable changes in body composition in the present study may be due to the length of treatment and because we did not prescribe any changes in diet or physical activity.
It may be worth mentioning that the few clinical trials that reported a decrease in IR did not do so with BMI values in their population [64,65,73]. We believe it may be helpful to consider the parameter of body and abdominal fat or BMI in clinical trials that analyze the effect of silymarin administration on IR in obese/overweight populations since adipose tissue in overweight or obese states exerts inflammatory effects that alter insulin signaling and induce IR [102,103,104]. Importantly, individuals with IR are at high risk of developing prediabetes and T2DM [11,105]. Yet, clinicians do not routinely measure insulin levels, partly because clinical guidelines do not integrate measures of IR, and other methods for diagnosing prediabetes and T2DM are used [11,89,105]. Similarly, clinicians do not routinely perform the OGTT. In our study, IR and prediabetes were present; the latter was detected at two hours post-glucose load during the OGTT and not through FPG levels, which were in the normal range. Therefore, IR and prediabetes may go undetected by usual methods of diagnosis in a population at risk. We believe it would be advantageous if clinicians employed several tests to detect IR, prediabetes, or T2DM, especially in the at-risk population, since individuals may have undetected hyperglycemia. Lifestyle changes are the general recommendation to prevent or delay the onset of T2DM after IR is detected. It is important to note that although HOMA-IR baseline levels decreased significantly in the present study after 12 weeks of treatment (3.6 ± 1.2 vs. 2.8 ± 0.9, p = 0.048), IR was still present in our study population, according to the IR inclusion criteria employed (HOMA-IR ≤ 2.6). A lengthier treatment may have allowed for a further decrease in IR.
One of the main limitations of the present study is the small sample size, which may have prevented significant differences from being observed in other parameters. Another possible limitation is the inclusion of only female patients in our study sample, as some studies have reported sex-dependent differences in response to silymarin treatment [106,107]. Furthermore, we did not stratify the population in our study according to the female reproductive cycle; some individuals may respond differently to silymarin treatment according to hormone levels within the female reproductive cycle and during menopause [106,108,109,110]. Menopause typically occurs between the ages of 47 and 49 in Mexican women, yet the criterion for premature menopause is 40 or less [111]. Therefore, some study participants may have been perimenopausal or transitioning to menopause. In addition, we did not determine HOMA-IR according to the menstrual cycle, and slight variations in IR may have occurred according to the menstrual phase to which premenopausal women were transitioning. Estradiol and progesterone are positively associated with IR [112], and the levels of these hormones vary during the menstrual cycle. A final possible limitation of the present study was the length of treatment. Even though we observed significant changes in IR after silymarin treatment (t = 12 weeks), a lengthier treatment may have allowed for observable differences in other parameters. Indeed, other studies reported a significant improvement in IR after 90 days or three months. However, in these studies, silymarin was given together with standard T2DM treatment [67,69], combined with B. aristata in T2DM patients [113], or combined with Vit E in HCV or NAFLD patients [74].
In individuals with an IR diagnosis, lifestyle modifications that include dietary therapy and physical activity are recommended to reduce visceral and body fat and sensitize muscle tissue to insulin [11,114,115]. Currently, there are no medications to treat IR alone, and pharmacological treatment for glycemic control can lead to undesirable side effects. Treatment with silymarin may be an alternative to help reduce IR caused by low-grade inflammation found in obesity [11,20,116]. A decrease in IR may help to prevent or delay the onset of T2DM, which is often reached within ten to fifteen years after IR appears [11]. The results showed that treatment with silymarin significantly decreased IR in a population of non-diabetic women with obesity and IR, which may have contributed to delaying the onset of T2DM. However, more clinical studies in IR-obese individuals with silymarin alone or with other interventions, such as changes in diet and physical activity, are needed to strengthen the results of this study.

4. Materials and Methods

4.1. Inclusion and Exclusion Criteria for Patient Recruitment

The current pilot study was authorized and performed at the Hospital General de México, Dr. Eduardo Liceaga in Mexico City (registry number D1-15-UME-04-066). The recruitment of patients took place between 2018 and 2020. We recruited six female patients from the Clínica de Atención Integral al Paciente con Obesidad y Diabetes who underwent the OGTT two weeks or less before enrollment. The inclusion criteria were willingness to participate in this study, age 18–45 years, with a BMI of 30–39.9 according to WHO diagnostic criteria, and a HOMA-IR ≥ 2.6 [117,118,119]. Exclusion criteria were patients with T2DM, dyslipidemia requiring pharmacological treatment, alcoholism or drug addiction, chronic infectious diseases, the Human Immunodeficiency Virus, chronic hepatitis, systemic arterial hypertension, auto-immune or chronic inflammatory diseases, who ingested antioxidant multivitamin supplements or nonsteroidal anti-inflammatory drugs 15 days before enrollment, or who were undergoing pharmacological treatment with monoamine oxidase (MAO)-inhibiting antidepressants, and smokers.

4.2. Metabolic Intervention

All patients were given silymarin (Neocholal-S®, Italmex Pharma, Ciudad de México, Mexico) and asked to take one capsule twice daily for twelve weeks. Each soft gelatin capsule contains a dry extract from Silybum marianum (151.5 mg, equivalent to 45 mg of silybins) [120]. We assessed adverse effects during each of the seven visits. Patients were instructed not to modify their eating or physical activity habits, not to ingest antioxidant multivitamin supplements or NSAIDs throughout the treatment and asked to report any changes in diet or physical activity.

4.3. Diet and Physical Activity Questionnaires

We obtained clinical nutritional history, 24 h dietary recall (24HR), habitual diet, food frequency, and validated physical activity questionnaires from enrolled patients at the beginning of our study from a clinical nutritionist to avoid significant variations in diet and physical activity [121,122,123]. Then, we saw patients every two weeks during six follow-up visits and obtained 24HR at every visit to monitor changes in diet.

4.4. Anthropometric Measurements and Determination of Insulin Resistance

We measured patient height with a stadiometer (Seca, model 206, Hamburg, Germany) on the first visit according to Lohman’s technique [124]. On the first and six subsequent visits, weight (kg), body fat (%), visceral fat (%), skeletal muscle (%), and BMI measurements were obtained from each patient with a bioimpedance scale (Omron Healthcare, model HBF-514C, Lake Forest, IL, USA). Waist and hip circumferences were measured according to Lohman’s technique [124]. Insulin sensitivity was estimated using the HOMA-IR (units of mass) [100].

4.5. Blood Sampling for Oral Glucose Tolerance Test

All patients underwent an OGTT before initiating and after completing 12 weeks of silymarin treatment. For the OGTT, fasting blood samples were obtained from all patients and then asked to ingest 75 g of an anhydrous glucose solution immediately after. Then, we collected blood samples from each patient at 30, 60, 90, and 120 min.

4.6. Biochemical Markers

We obtained blood chemistry analyses, lipid profiles, and determination of insulin levels from the blood samples of all patients, processed at the Hospital General de Mexico, Dr. Eduardo Liceaga laboratory service.

4.7. Statistical Analysis

We analyzed the normality of the data with the Kolmogorov–Smirnov test. Then, we analyzed datasets that passed normality tests by measuring changes in the same patient before (t = 0 weeks) and after silymarin treatment (t = 12 weeks). We evaluated the data with the Student’s t-test for paired samples, with a 95% CI. p values < 0.05 were considered statistically significant. We performed all tests using GraphPad Prism® 5.0 software (GraphPad Software, Boston, MA, USA).

5. Conclusions

Silymarin treatment alone significantly reduced glucose and HOMA-IR levels in a group of IR non-diabetic obese women after twelve weeks of treatment, without standard treatment, dietary, or physical activity intervention. The results of our study support the benefits of silymarin in obese individuals with IR. However, more clinical studies in IR-obese individuals with silymarin treatment and a larger sample size are needed to strengthen the results of this study.

Supplementary Materials

The supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms25042050/s1.

Author Contributions

Conceptualization, M.C. and K.M.-R.; patient recruiting and sample collection, K.M.-R. and A.M.; methodology, M.C. and K.M.-R.; formal analysis, M.C. and K.M.-R.; investigation, K.M.-R.; resources, M.C. and A.M.; writing—original draft preparation, K.M.-R.; writing—review and editing, M.C., K.M.-R., M.B.-B. and A.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the General Hospital of Mexico Dr. Eduardo Liceaga in Mexico City, registry number D1-15-UME-04-066, approved on 9 November 2015. We carried out all procedures under the Regulation of the General Health Law on Health Research provisions, Title Two, Chapter I, Article 17, Section II, Research with minimal risk for Mexico.

Informed Consent Statement

All participants signed a written informed consent form before enrollment. Written informed consent was obtained from the patients to publish this paper.

Data Availability Statement

We included the original contributions presented in our study in the article; please direct further inquiries to the corresponding authors.

Acknowledgments

Karla María Mac Donald Ramos is a doctoral student from the Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM) and has received CONAHCYT fellowship 607933 (CVU 780099). We are grateful to Italmex Pharma, Mexico, for providing Neocholal-S®. Marco Cerbón received a sabbatical fellowship from PASPA-DGAPA, UNAM.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Obesity. Available online: https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3420 (accessed on 27 August 2021).
  2. Obesity and Overweight. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 27 August 2021).
  3. Boutari, C.; Mantzoros, C.S. A 2022 update on the epidemiology of obesity and a call to action: As its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 2022, 133, 155217. [Google Scholar] [CrossRef] [PubMed]
  4. Panuganti, K.; Nguyen, M. Obesity—StatPearls—NCBI Bookshelf. Available online: https://www.ncbi.nlm.nih.gov/books/NBK459357/ (accessed on 20 August 2021).
  5. Rohm, T.V.; Meier, D.T.; Olefsky, J.M.; Donath, M.Y. Inflammation in Obesity, Diabetes, and Related Disorders. Immunity 2022, 55, 31–55. [Google Scholar] [CrossRef] [PubMed]
  6. Ellulu, M.S.; Patimah, I.; Khaza’ai, H.; Rahmat, A.; Abed, Y. Obesity and Inflammation: The Linking Mechanism and the Complications. Arch. Med. Sci. 2017, 4, 851–863. [Google Scholar] [CrossRef] [PubMed]
  7. Esser, N.; Legrand-Poels, S.; Piette, J.; Scheen, A.J.; Paquot, N. Inflammation as a Link between Obesity, Metabolic Syndrome and Type 2 Diabetes. Diabetes Res. Clin. Pract. 2014, 105, 141–150. [Google Scholar] [CrossRef] [PubMed]
  8. MacDonald-Ramos, K.; Vega-Sánchez, R. Maternal Adiposity Is Associated with Inflammatory Gene Expression in Leukocytes at Term Human Pregnancy: A Pilot Study. Mol. Genet. Genom. Med. 2020, 9, e1570. [Google Scholar] [CrossRef]
  9. Yung, J.H.M.; Giacca, A. Role of C-Jun N-Terminal Kinase (JNK) in Obesity and Type 2 Diabetes. Cells 2020, 9, 706. [Google Scholar] [CrossRef]
  10. Mraz, M.; Haluzik, M. The Role of Adipose Tissue Immune Cells in Obesity and Low-Grade Inflammation. J. Endocrinol. 2014, 222, 113–127. [Google Scholar] [CrossRef]
  11. Freeman, A.M.; Pennings, N. Insulin Resistance—StatPearls—NCBI Bookshelf; StatPearls Publising LLC.: Treasure Island, FL, USA, 2019. [Google Scholar]
  12. Marchesini, G.; Brizi, M.; Morselli-Labate, A.M.; Bianchi, G.; Bugianesi, E.; McCullough, A.J.; Forlani, G.; Melchionda, N. Association of Nonalcoholic Fatty Liver Disease with Insulin Resistance. Am. J. Med. 1999, 107, 450–455. [Google Scholar] [CrossRef]
  13. Kitade, H.; Chen, G.; Ni, Y.; Ota, T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients 2017, 9, 387. [Google Scholar] [CrossRef] [PubMed]
  14. NIDDK. Insulin Resistance & Prediabetes|NIDDK; National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA, 2018. [Google Scholar]
  15. Silymarin|C25H22O10—PubChem. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/1548994 (accessed on 16 May 2020).
  16. Silybum marianum (Fruit)—AHPA Botanical Identity References Compendium. Available online: http://www.botanicalauthentication.org/index.php/Silybum_marianum_(fruit) (accessed on 5 June 2020).
  17. Silybum marianum—Wikidata. Available online: https://www.wikidata.org/wiki/Q193798 (accessed on 5 June 2020).
  18. Kren, V.; Walterová, D. Silybin and Silymarin--New Effects and Applications. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2005, 149, 29–41. [Google Scholar] [CrossRef] [PubMed]
  19. Wellington, K.; Jarvis, B. Silymarin: A Review of Its Clinical Properties in the Management of Hepatic Disorders. BioDrugs 2001, 15, 465–489. [Google Scholar] [CrossRef] [PubMed]
  20. MacDonald-Ramos, K.; Michán, L.; Martínez-Ibarra, A.; Cerbón, M. Silymarin Is an Ally against Insulin Resistance: A Review. Ann. Hepatol. 2021, 23, 100255. [Google Scholar] [CrossRef] [PubMed]
  21. Tajmohammadi, A.; Razavi, B.M.; Hosseinzadeh, H. Silybum marianum (Milk Thistle) and Its Main Constituent, Silymarin, as a Potential Therapeutic Plant in Metabolic Syndrome: A Review. Phytother. Res. 2018, 32, 1933–1949. [Google Scholar] [CrossRef] [PubMed]
  22. Federico, A.; Dallio, M.; Loguercio, C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules 2017, 22, 191. [Google Scholar] [CrossRef] [PubMed]
  23. Gillessen, A.; Schmidt, H.H.J. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv. Ther. 2020, 37, 1279–1301. [Google Scholar] [CrossRef]
  24. Abenavoli, L.; Milic, N. Silymarin for Liver Disease. In Liver Pathophysiology; Academic Press: London, UK, 2017; pp. 621–631. [Google Scholar] [CrossRef]
  25. Skottová, N.; Krecman, V. Silymarin as a Potential Hypocholesterolaemic Drug. Physiol. Res. 1998, 47, 1–7. [Google Scholar]
  26. Abenavoli, L.; Izzo, A.A.; Milić, N.; Cicala, C.; Santini, A.; Capasso, R. Milk Thistle (Silybum marianum): A Concise Overview on Its Chemistry, Pharmacological, and Nutraceutical Uses in Liver Diseases. Phytother. Res. 2018, 32, 2202–2213. [Google Scholar] [CrossRef] [PubMed]
  27. Hadi, A.; Pourmasoumi, M.; Mohammadi, H.; Symonds, M.; Miraghajani, M. The Effects of Silymarin Supplementation on Metabolic Status and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Clinical Trials. Complement. Ther. Med. 2018, 41, 311–319. [Google Scholar] [CrossRef]
  28. Bijak, M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)—Chemistry, Bioavailability, and Metabolism. Molecules 2017, 22, 1942. [Google Scholar] [CrossRef] [PubMed]
  29. Surai, P.F. Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives. Antioxidants 2015, 4, 204–247. [Google Scholar] [CrossRef]
  30. Tuli, H.S.; Mittal, S.; Aggarwal, D.; Parashar, G.; Parashar, N.C.; Upadhyay, S.K.; Barwal, T.S.; Jain, A.; Kaur, G.; Savla, R.; et al. Path of Silibinin from Diet to Medicine: A Dietary Polyphenolic Flavonoid Having Potential Anti-Cancer Therapeutic Significance. Semin. Cancer Biol. 2021, 73, 196–218. [Google Scholar] [CrossRef]
  31. Škottová, N.; Kazdová, L.; Oliyarnyk, O.; Večeřa, R.; Sobolová, L.; Ulrichová, J. Phenolics-Rich Extracts from Silybum marianum and Prunella Vulgaris Reduce a High-Sucrose Diet Induced Oxidative Stress in Hereditary Hypertriglyceridemic Rats. Pharmacol. Res. 2004, 50, 123–130. [Google Scholar] [CrossRef] [PubMed]
  32. Soto, C.; Mena, R.; Luna, J.; Cerbón, M.; Larrieta, E.; Vital, P.; Uría, E.; Sánchez, M.; Recoba, R.; Barrón, H.; et al. Silymarin Induces Recovery of Pancreatic Function after Alloxan Damage in Rats. Life Sci. 2004, 75, 2167–2180. [Google Scholar] [CrossRef] [PubMed]
  33. Das, S.; Roy, P.; Pal, R.; Auddy, R.G.; Chakraborti, A.S.; Mukherjee, A. Engineered Silybin Nanoparticles Educe Efficient Control in Experimental Diabetes. PLoS ONE 2014, 9, e101818. [Google Scholar] [CrossRef]
  34. Soto, C.; Raya, L.; Pérez, J.; González, I.; Pérez, S. Silymarin Induces Expression of Pancreatic Nkx6.1 Transcription Factor and β-Cells Neogenesis in a Pancreatectomy Model. Molecules 2014, 19, 4654–4668. [Google Scholar] [CrossRef] [PubMed]
  35. Soto, C.; Raya, L.; Juárez, J.; Pérez, J.; González, I. Effect of Silymarin in Pdx-1 Expression and the Proliferation of Pancreatic β-Cells in a Pancreatectomy Model. Phytomedicine 2014, 21, 233–239. [Google Scholar] [CrossRef] [PubMed]
  36. Poruba, M.; Matušková, Z.; Kazdová, L.; Oliyarnyk, O.; Malínská, H.; Tozzi di Angelo, I.; Večeřa, R. Positive Effects of Different Drug Forms of Silybin in the Treatment of Metabolic Syndrome. Physiol. Res. 2015, 64, S507–S512. [Google Scholar] [CrossRef] [PubMed]
  37. Poruba, M.; Kazdová, L.; Oliyarnyk, O.; Malinská, H.; Matusková, Z.; Tozzi Di Angelo, I.; Skop, V.; Vecera, R. Improvement Bioavailability of Silymarin Ameliorates Severe Dyslipidemia Associated with Metabolic Syndrome. Xenobiotica 2015, 45, 751–756. [Google Scholar] [CrossRef]
  38. Tuorkey, M.J.; El-Desouki, N.I.; Kamel, R.A. Cytoprotective Effect of Silymarin against Diabetes-Induced Cardiomyocyte Apoptosis in Diabetic Rats. Biomed. Environ. Sci. 2015, 28, 36–43. [Google Scholar] [CrossRef] [PubMed]
  39. Vecchione, G.; Grasselli, E.; Voci, A.; Baldini, F.; Grattagliano, I.; Wang, D.Q.; Portincasa, P.; Vergani, L. Silybin Counteracts Lipid Excess and Oxidative Stress in Cultured Steatotic Hepatic Cells. World J. Gastroenterol. 2016, 22, 6016–6026. [Google Scholar] [CrossRef]
  40. Zhang, B.; Xu, D.; She, L.; Wang, Z.; Yang, N.; Sun, R.; Zhang, Y.; Yan, C.; Wei, Q.; Aa, J.; et al. Silybin Inhibits NLRP3 Inflammasome Assembly through the NAD+/SIRT2 Pathway in Mice with Nonalcoholic Fatty Liver Disease. FASEB J. 2018, 32, 757–767. [Google Scholar] [CrossRef]
  41. Liu, Y.; Xu, W.; Zhai, T.; You, J.; Chen, Y. Silibinin Ameliorates Hepatic Lipid Accumulation and Oxidative Stress in Mice with Non-Alcoholic Steatohepatitis by Regulating CFLAR-JNK Pathway. Acta Pharm. Sin. B 2019, 9, 745–757. [Google Scholar] [CrossRef] [PubMed]
  42. Yao, J.; Zhi, M.; Chen, M. Effect of Silybin on High-Fat-Induced Fatty Liver in Rats. Braz. J. Med. Biol. Res. 2011, 44, 652–659. [Google Scholar] [CrossRef]
  43. Sayin, F.K.; Buyukbas, S.; Basarali, M.K.; Alp, H.; Toy, H.; Ugurcu, V. Effects of Silybum marianum Extract on High-Fat Diet Induced Metabolic Disorders in Rats. Pol. J. Food Nutr. Sci. 2016, 66, 43–49. [Google Scholar] [CrossRef]
  44. Lama, S.; Vanacore, D.; Diano, N.; Nicolucci, C.; Errico, S.; Dallio, M.; Federico, A.; Loguercio, C.; Stiuso, P. Ameliorative Effect of Silybin on Bisphenol A Induced Oxidative Stress, Cell Proliferation and Steroid Hormones Oxidation in HepG2 Cell Cultures. Sci. Rep. 2019, 9, 3228. [Google Scholar] [CrossRef] [PubMed]
  45. Sorrentino, G.; Crispino, P.; Coppola, D.; De Stefano, G. Efficacy of Lifestyle Changes in Subjects with Non-Alcoholic Liver Steatosis and Metabolic Syndrome May Be Improved with an Antioxidant Nutraceutical: A Controlled Clinical Study. Drugs R&D 2015, 15, 21–25. [Google Scholar] [CrossRef]
  46. Khalili, N.; Fereydoonzadeh, R.; Mohtashami, R.; Mehrzadi, S.; Heydari, M.; Huseini, H.F. Silymarin, Olibanum, and Nettle, a Mixed Herbal Formulation in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. J. Evid.-Based Complement. Altern. Med. 2017, 22, 603–608. [Google Scholar] [CrossRef] [PubMed]
  47. Zarvandi, M.; Rakhshandeh, H.; Abazari, M.; Shafiee-Nick, R.; Ghorbani, A. Safety and Efficacy of a Polyherbal Formulation for the Management of Dyslipidemia and Hyperglycemia in Patients with Advanced-Stage of Type-2 Diabetes. Biomed. Pharmacother. 2017, 89, 69–75. [Google Scholar] [CrossRef]
  48. Ebrahimpour Koujan, S.; Gargari, B.P.; Mobasseri, M.; Valizadeh, H.; Asghari-Jafarabadi, M. Effects of Silybum marianum (L.) Gaertn. (Silymarin) Extract Supplementation on Antioxidant Status and Hs-CRP in Patients with Type 2 Diabetes Mellitus: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. Phytomedicine 2015, 22, 290–296. [Google Scholar] [CrossRef]
  49. Javed, S.; Kohli, K.; Ali, M. Reassessing Bioavailability of Silymarin. Altern. Med. Rev. 2011, 16, 239–249. [Google Scholar] [PubMed]
  50. Di Costanzo, A.; Angelico, R. Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art. Molecules 2019, 24, 2155. [Google Scholar] [CrossRef] [PubMed]
  51. Kidd, P.; Head, K. A Review of the Bioavailability and Clinical Efficacy of Milk Thistle Phytosome: A Silybin-Phosphatidylcholine Complex (Siliphos®). Altern. Med. Rev. 2005, 10, 193–203. [Google Scholar] [PubMed]
  52. Méndez-Sánchez, N.; Dibildox-Martinez, M.; Sosa-Noguera, J.; Sánchez-Medal, R.; Flores-Murrieta, F.J. Superior Silybin Bioavailability of Silybin-Phosphatidylcholine Complex in Oily-Medium Soft-Gel Capsules versus Conventional Silymarin Tablets in Healthy Volunteers. BMC Pharmacol. Toxicol. 2019, 20, 5. [Google Scholar] [CrossRef]
  53. Li Volti, G.; Salomone, S.; Sorrenti, V.; Mangiameli, A.; Urso, V.; Siarkos, I.; Galvano, F.; Salamone, F. Effect of Silibinin on Endothelial Dysfunction and ADMA Levels in Obese Diabetic Mice. Cardiovasc. Diabetol. 2011, 10, 62. [Google Scholar] [CrossRef] [PubMed]
  54. Yao, J.; Zhi, M.; Gao, X.; Hu, P.; Li, C.; Yang, X. Effect and the Probable Mechanisms of Silibinin in Regulating Insulin Resistance in the Liver of Rats with Non-Alcoholic Fatty Liver. Braz. J. Med. Biol. Res. 2013, 46, 270–277. [Google Scholar] [CrossRef]
  55. Zhang, Y.; Hai, J.; Cao, M.; Zhang, Y.; Pei, S.; Wang, J.; Zhang, Q. Silibinin Ameliorates Steatosis and Insulin Resistance during Non-Alcoholic Fatty Liver Disease Development Partly through Targeting IRS-1/PI3K/Akt Pathway. Int. Immunopharmacol. 2013, 17, 714–720. [Google Scholar] [CrossRef] [PubMed]
  56. Cheng, K.C.; Asakawa, A.; Li, Y.X.; Chung, H.H.; Amitani, H.; Ueki, T.; Cheng, J.T.; Inui, A. Silymarin Induces Insulin Resistance through an Increase of Phosphatase and Tensin Homolog in Wistar Rats. PLoS ONE 2014, 9, e84550. [Google Scholar] [CrossRef]
  57. Bouderba, S.; Sanchez-Martin, C.; Villanueva, G.R.; Detaille, D.; Koceïr, E.A. Beneficial Effects of Silibinin against the Progression of Metabolic Syndrome, Increased Oxidative Stress, and Liver Steatosis in Psammomys Obesus, a Relevant Animal Model of Human Obesity and Diabetes. J. Diabetes 2014, 6, 184–192. [Google Scholar] [CrossRef]
  58. Li, H.B.; Yang, Y.R.Y.; Mo, Z.J.; Ding, Y.; Jiang, W.J. Silibinin Improves Palmitate-Induced Insulin Resistance in C2C12 Myotubes by Attenuating IRS-1/PI3K/AKt Pathway Inhibition. Braz. J. Med. Biol. Res. 2015, 48, 440–446. [Google Scholar] [CrossRef]
  59. Feng, B.; Meng, R.; Huang, B.; Shen, S.; Bi, Y.; Zhu, D. Silymarin Alleviates Hepatic Oxidative Stress and Protects against Metabolic Disorders in High-Fat Diet-Fed Mice. Free Radic. Res. 2016, 50, 314–327. [Google Scholar] [CrossRef]
  60. Gu, M.; Zhao, P.; Huang, J.; Zhao, Y.; Wang, Y.; Li, Y.; Li, Y.; Fan, S.; Ma, Y.M.; Tong, Q.; et al. Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. Front. Pharmacol. 2016, 7, 345. [Google Scholar] [CrossRef]
  61. Alsaggar, M.; Bdour, S.; Ababneh, Q.; El-Elimat, T.; Qinna, N.; Alzoubi, K.H. Silibinin Attenuates Adipose Tissue Inflammation and Reverses Obesity and Its Complications in Diet-Induced Obesity Model in Mice. BMC Pharmacol. Toxicol. 2020, 21, 8. [Google Scholar] [CrossRef]
  62. Velussi, M.; Cernigoi, A.M.; Viezzoli, L.; Dapas, F.; Caffau, C.; Zilli, M. Silymarin Reduces Hyperinsulinemia, Malondialdehyde Levels, and Daily Insulin Need in Cirrhotic Diabetic Patients. Curr. Ther. Res. 1993, 53, 533–545. [Google Scholar] [CrossRef]
  63. Velussi, M.; Cernigoi, A.M.; Ariella, D.M.; Dapas, F.; Caffau, C.; Zilli, M.; De Monte, A.; Dapas, F.; Caffau, C.; Zilli, M.; et al. Long-Term (12 Months) Treatment with an Anti-Oxidant Drug (Silymarin) Is Effective on Hyperinsulinemia, Exogenous Insulin Need and Malondialdehyde Levels in Cirrhotic Diabetic Patients. J. Hepatol. 1997, 26, 871–879. [Google Scholar] [CrossRef]
  64. Lirussi, F.; Beccarello, A.; Zanette, G.; De Monte, A.; Donadon, V.; Velussi, M.; Crepaldi, G. Silybin-β-Cyclodextrin in the Treatment of Patients with Diabetes Mellitus and Alcoholic Liver Disease. Efficacy Study of a New Preparation of an Anti-Oxidant Agent. Diabetes Nutr. Metab.-Clin. Exp. 2002, 15, 222–231. [Google Scholar]
  65. Huseini, H.F.; Larijani, B.; Heshmat, R.; Fakhrzadeh, H.; Radjabipour, B.; Toliat, T.; Raza, M. The Efficacy of Silybum marianum (L.) Gaertn. (Silymarin) in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Phytother. Res. 2006, 20, 1036–1039. [Google Scholar] [CrossRef] [PubMed]
  66. di Pierro, F.; Villanova, N.; Agostini, F.; Marzocchi, R.; Soverini, V.; Marchesini, G. Pilot Study on the Additive Effects of Berberine and Oral Type 2 Diabetes Agents for Patients with Suboptimal Glycemic Control. Diabetes Metab. Syndr. Obes. 2012, 5, 213–217. [Google Scholar] [CrossRef] [PubMed]
  67. Elgarf, T.A.; Mahdy, M.M.; Sabri, N.A. Effect of Silymarin Supplementation on Glycemic Control, Lipid Profile and Insulin Resistance in Patients with Type 2 Diabetes Mellitus. Int. J. Adv. Res. 2015, 3, 812–821. [Google Scholar]
  68. Guarino, G.; Strollo, F.; Carbone, L.; Della Corte, T.; Letizia, M.; Marino, G.; Gentile, S. Bioimpedance Analysis, Metabolic Effects and Safety of the Association Berberis Aristataisilybum Marianum: A 52-Week Double-Blind, Placebo-Controlled Study in Obese Patients with Type 2 Diabetes. J. Biol. Regul. Homeost. Agents 2017, 31, 495–502. [Google Scholar]
  69. Ebrahimpour-koujan, S.; Gargari, B.P.; Mobasseri, M.; Valizadeh, H.; Asghari-Jafarabadi, M. Lower Glycemic Indices and Lipid Profile among Type 2 Diabetes Mellitus Patients Who Received Novel Dose of Silybum marianum (L.) Gaertn. (Silymarin) Extract Supplement: A Triple-Blinded Randomized Controlled Clinical Trial. Phytomedicine 2018, 44, 39–44. [Google Scholar] [CrossRef] [PubMed]
  70. Trappoliere, M.; Federico, A.; Tuccillo, C.; De Sio, I.; Di Leva, A.; Niosi, M.; D’Auria, M.; Loguercio, C.; Cimino, L.; De Girolamo, V.; et al. Effects of a New Pharmacological Complex (Sylibin+vitamin E+phospholipids) on Some Markers of Metabolic Syndrome and of a Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease: A Preliminary Open Pilot Study. Minerva Gastroenterol. Dietol. 2005, 51, 193–199. [Google Scholar] [PubMed]
  71. Federico, A.; Trappoliere, M.; Tuccillo, C.; De Sio, I.; Di Leva, A.; Del Vecchio Blanco, C.; Loguercio, C. A New Silybin-Vitamin E-Phospholipid Complex Improves Insulin Resistance and Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease: Preliminary Observations. Gut 2006, 55, 901–902. [Google Scholar] [CrossRef] [PubMed]
  72. Loguercio, C.; Federico, A.; Trappoliere, M.; Tuccillo, C.; De Sio, I.; Di Leva, A.; Niosi, M.; D’Auria, M.V.; Capasso, R.; Blanco, C.D.V.; et al. The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig. Dis. Sci. 2007, 52, 2387–2395. [Google Scholar] [CrossRef] [PubMed]
  73. Yin-quan, D.; Xiao-fen, F.; Jian-ping, L.; Deng, Y.Q.; Fan, X.F.; Li, J.P. The State of Insulin Resistance in Patients with Nonalcoholic Fatty Liver and the Intervention with Gankangyin. Chin. J. Integr. Med. 2005, 11, 117–122. [Google Scholar] [CrossRef] [PubMed]
  74. Falasca, K.; Ucciferri, C.; Mancino, P.; Vitacolonna, E.; De Tullio, D.; Pizzigallo, E.; Conti, P.; Vecchiet, J. Treatment with Silybin-Vitamin E-Phospholipid Complex in Patients with Hepatitis C Infection. J. Med. Virol. 2008, 80, 1900–1906. [Google Scholar] [CrossRef] [PubMed]
  75. Loguercio, C.; Andreone, P.; Brisc, C.; Brisc, M.C.; Bugianesi, E.; Chiaramonte, M.; Cursaro, C.; Danila, M.; De Sio, I.; Floreani, A.; et al. Silybin Combined with Phosphatidylcholine and Vitamin e in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Free Radic. Biol. Med. 2012, 52, 1658–1665. [Google Scholar] [CrossRef] [PubMed]
  76. Abenavoli, L.; Greco, M.; Nazionale, I.; Peta, V.; Milic, N.; Accattato, F.; Foti, D.; Gulletta, E.; Luzza, F. Effects of Mediterranean Diet Supplemented with Silybin-Vitamin E-Phospholipid Complex in Overweight Patients with Non-Alcoholic Fatty Liver Disease. Expert Rev. Gastroenterol. Hepatol. 2015, 9, 519–527. [Google Scholar] [CrossRef]
  77. Aller, R.; Izaola, O.; Gómez, S.; Tafur, C.; González, G.; Berroa, E.; Mora, N.; González, J.M.; De Luis, D.A. Effect of Silymarin plus Vitamin E in Patients with Non-Alcoholic Fatty Liver Disease. A Randomized Clinical Pilot Study. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 3118–3124. [Google Scholar]
  78. Aller, R.; Laserna, C.; Rojo, M.Á.; Mora, N.; García, C.; Pina, M.; Sigüenza, R.; Durà, M.; Primo, D.; Izaola, O.; et al. Role of the PNPLA3 Polymorphism Rs738409 on Silymarin + Vitamin E Response in Subjects with Non-Alcoholic Fatty Liver Disease. Rev. Esp. Enfermedades Dig. 2018, 110, 634–640. [Google Scholar] [CrossRef] [PubMed]
  79. Federico, A.; Dallio, M.; Gravina, A.G.; Diano, N.; Errico, S.; Masarone, M.; Romeo, M.; Tuccillo, C.; Stiuso, P.; Morisco, F.; et al. The Bisphenol a Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. Int. J. Environ. Res. Public Health 2020, 17, 3369. [Google Scholar] [CrossRef]
  80. Derosa, G.; Bonaventura, A.; Bianchi, L.; Romano, D.; D’Angelo, A.; Fogari, E.; Maffioli, P. Effects of Berberis aristata/Silybum marianum Association on Metabolic Parameters and Adipocytokines in Overweight Dyslipidemic Patients. J. Biol. Regul. Homeost. Agents 2013, 27, 717–728. [Google Scholar]
  81. Derosa, G.; Romano, D.; D’Angelo, A.; Maffioli, P. Berberis aristata/Silybum marianum Fixed Combination (Berberol®) Effects on Lipid Profile in Dyslipidemic Patients Intolerant to Statins at High Dosages: A Randomized, Placebo-Controlled, Clinical Trial. Phytomedicine 2015, 22, 231–237. [Google Scholar] [CrossRef] [PubMed]
  82. Derosa, G.; Romano, D.; D’Angelo, A.; Maffioli, P. Berberis aristata Combined with Silybum marianum on Lipid Profile in Patients Not Tolerating Statins at High Doses. Atherosclerosis 2015, 239, 87–92. [Google Scholar] [CrossRef] [PubMed]
  83. Derosa, G.; D’Angelo, A.; Romano, D.; Maffioli, P.; Giuseppe, D.; Angela, D.; Davide, R.; Pamela, M.; Derosa, G.; D’Angelo, A.; et al. Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. Int. J. Mol. Sci. 2017, 18, 343. [Google Scholar] [CrossRef] [PubMed]
  84. Fogacci, F.; Grassi, D.; Rizzo, M.; Cicero, A.F.G. Metabolic Effect of Berberine–Silymarin Association: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Clinical Trials. Phytother. Res. 2019, 33, 862–870. [Google Scholar] [CrossRef] [PubMed]
  85. Cicero, A.F.G.; Fogacci, F.; Giovannini, M.; D’addato, S.; Grandi, E. Nutraceuticals Effect of Dietary Supplementation with a New Nutraceutical Formulation on Cardiometabolic Risk Factors: A Double-Blind, Placebo-Controlled, Randomized Clinical Study. Arch. Med. Sci. Atheroscler. Dis. 2023, 8, 53–59. [Google Scholar] [CrossRef]
  86. Nehmi-Filho, V.; Santamarina, A.B.; de Freitas, J.A.; Trarbach, E.B.; de Oliveira, D.R.; Palace-Berl, F.; de Souza, E.; de Miranda, D.A.; Escamilla-Garcia, A.; Otoch, J.P.; et al. Novel Nutraceutical Supplements with Yeast β-Glucan, Prebiotics, Minerals, and Silybum marianum (Silymarin) Ameliorate Obesity-Related Metabolic and Clinical Parameters: A Double-Blind Randomized Trial. Front. Endocrinol. 2023, 13, 1089938. [Google Scholar] [CrossRef]
  87. Tschritter, O.; Fritsche, A.; Shirkavand, F.; Machicao, F.; Häring, H.; Stumvoll, M. Assessing the Shape of the Glucose Curve during an Oral Glucose Tolerance Test. Diabetes Care 2003, 26, 1026–1033. [Google Scholar] [CrossRef] [PubMed]
  88. Kim, J.Y.; Michaliszyn, S.F.; Nasr, A.; Lee, S.J.; Tfayli, H.; Hannon, T.; Hughan, K.S.; Bacha, F.; Arslanian, S. The Shape of the Glucose Response Curve during an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth. Diabetes Care 2016, 39, 1431–1439. [Google Scholar] [CrossRef]
  89. Secretaría de Salud (SS). Norma Oficial Mexicana Nom-015-Ssa2-2010, Para La Prevención, Tratamiento y Control de La Diabetes Mellitus. D. Of. Fed. 2010, 1, 1–40. [Google Scholar]
  90. Diabetes by Region—IDF DIABETES ATLAS—NCBI Bookshelf. Available online: https://www.ncbi.nlm.nih.gov/books/NBK581938/ (accessed on 9 September 2022).
  91. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2014, 37, S81–S90. [Google Scholar] [CrossRef]
  92. World Health Organization & International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation. Available online: https://www.who.int/publications/i/item/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia (accessed on 25 January 2022).
  93. Federico, A.; Dallio, M.; Masarone, M.; Gravina, A.G.; Di Sarno, R.; Tuccillo, C.; Cossiga, V.; Lama, S.; Stiuso, P.; Morisco, F.; et al. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. Oxid. Med. Cell Longev. 2019, 2019, 8742075. [Google Scholar] [CrossRef] [PubMed]
  94. Derosa, G.; Bonaventura, A.; Bianchi, L.; Romano, D.; D’angelo, A.; Fogari, E.; Maffioli, P. Berberis aristata/Silybum marianum Fixed Combination on Lipid Profile and Insulin Secretion in Dyslipidemic Patients. Expert Opin. Biol. Ther. 2013, 13, 1495–1506. [Google Scholar] [CrossRef]
  95. Kim, J.Y.; Mandarino, L.J.; Coletta, D.K.; Shaibi, G.Q. Glucose Response Curve and Type 2 Diabetes Risk in Latino Adolescents. Diabetes Care 2012, 35, 1925–1930. [Google Scholar] [CrossRef]
  96. Kaga, H.; Tamura, Y.; Takeno, K.; Kakehi, S.; Someya, Y.; Funayama, T.; Furukawa, Y.; Suzuki, R.; Sugimoto, D.; Kadowaki, S.; et al. Shape of the Glucose Response Curve during an Oral Glucose Tolerance Test Is Associated with Insulin Clearance and Muscle Insulin Sensitivity in Healthy Non-Obese Men. J. Diabetes Investig. 2020, 11, 874–877. [Google Scholar] [CrossRef] [PubMed]
  97. Morris, C.; O’Grada, C.; Ryan, M.; Roche, H.M.; Gibney, M.J.; Gibney, E.R.; Brennan, L. Identification of Differential Responses to an Oral Glucose Tolerance Test in Healthy Adults. PLoS ONE 2013, 8, e72890. [Google Scholar] [CrossRef]
  98. Cheng, X.; Yang, N.; Li, Y.; Sun, Q.; Qiu, L.; Xu, L.; Ping, F.; Li, W.; Zhang, H. The Shape of the Glucose Response Curve during an Oral Glucose Tolerance Test Heralds β-Cell Function in a Large Chinese Population. BMC Endocr. Disord. 2019, 19, 119. [Google Scholar] [CrossRef]
  99. Muniyappa, R.; Madan, R. Assessing Insulin Sensitivity and Resistance in Humans. In Endotext; MDText.com, Inc.: South Dartmouth, MA, USA, 2000. [Google Scholar]
  100. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis Model Assessment: Insulin Resistance and Beta-Cell Function from Fasting Plasma Glucose and Insulin Concentrations in Man. Diabetologia 1985, 28, 412–419. [Google Scholar] [CrossRef]
  101. Solis, G.R.O.; Hernandez, H.H.Y.I. Norma Oficial Mexicana NOM-037-SSA2-2012, Para La Prevención, Tratamiento y Control de Las Dislipidemias. Rev. Mex. Cardiol. 2013, 24, 3–22. [Google Scholar]
  102. McArdle, M.A.; Finucane, O.M.; Connaughton, R.M.; McMorrow, A.M.; Roche, H.M. Mechanisms of Obesity-Induced Inflammation and Insulin Resistance: Insights into the Emerging Role of Nutritional Strategies. Front. Endocrinol. 2013, 4, 52. [Google Scholar] [CrossRef]
  103. Tanti, J.F.; Ceppo, F.; Jager, J.; Berthou, F. Implication of Inflammatory Signaling Pathways in Obesity-Induced Insulin Resistance. Front. Endocrinol. 2013, 3, 181. [Google Scholar] [CrossRef]
  104. Zatterale, F.; Longo, M.; Naderi, J.; Raciti, G.A.; Desiderio, A.; Miele, C.; Beguinot, F. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front. Physiol. 2020, 10, 1607. [Google Scholar] [CrossRef]
  105. Alvarez, S.; Coffey, R.; Algotar, A.M.; Rosolová, H. Prediabetes; StatPearls Publishing: Treasure Island, FL, USA, 2022; Volume 68, pp. 82–84. [Google Scholar] [CrossRef]
  106. Dupuis, M.L.; Conti, F.; Maselli, A.; Pagano, M.T.; Ruggieri, A.; Anticoli, S.; Fragale, A.; Gabriele, L.; Gagliardi, M.C.; Sanchez, M.; et al. The Natural Agonist of Estrogen Receptor β Silibinin Plays an Immunosuppressive Role Representing a Potential Therapeutic Tool in Rheumatoid Arthritis. Front. Immunol. 2018, 9, 1903. [Google Scholar] [CrossRef]
  107. Shokouhi, G.; Kosari-Nasab, M.; Salari, A.A. Silymarin Sex-Dependently Improves Cognitive Functions and Alters TNF-α, BDNF, and Glutamate in the Hippocampus of Mice with Mild Traumatic Brain Injury. Life Sci. 2020, 257, 118049. [Google Scholar] [CrossRef] [PubMed]
  108. Seidlová-Wuttke, D.; Becker, T.; Christoffel, V.; Jarry, H.; Wuttke, W. Silymarin Is a Selective Estrogen Receptor β (ERβ) Agonist and Has Estrogenic Effects in the Metaphysis of the Femur but No or Antiestrogenic Effects in the Uterus of Ovariectomized (Ovx) Rats. J. Steroid Biochem. Mol. Biol. 2003, 86, 179–188. [Google Scholar] [CrossRef] [PubMed]
  109. Saberi, Z.; Gorji, N.; Memariani, Z.; Moeini, R.; Shirafkan, H.; Amiri, M. Evaluation of the Effect of Silybum marianum Extract on Menopausal Symptoms: A Randomized, Double-Blind Placebo-Controlled Trial. Phytother. Res. 2020, 34, 3359–3366. [Google Scholar] [CrossRef]
  110. Maleki, N.; Khosh Ravesh, R.; Salehiyeh, S.; Faisal Faiz, A.; Ebrahimi, M.; Sharbati, A.; Panji, M.; Ajami Khiyavi, H.; Safizadeh, F.; Abbasi, M.; et al. Comparative Effects of Estrogen and Silibinin on Cardiovascular Risk Biomarkers in Ovariectomized Rats. Gene 2022, 823, 146365. [Google Scholar] [CrossRef]
  111. Congreso, E.L.; Estados, G.D.E.L.O.S.; Mexicanos, U.; DOF—Diario Oficial de La Federación NORMA Oficial Mexicana NOM-035-SSA2-2012 Para La Prevención y Control de Enfermedades En La Perimenopausia y Postmenopausia de La Mujer. Criterios Para Brindar Atención Médica. Available online: https://diariooficial.gob.mx/normasOficiales.php?codp=5018&view=si# (accessed on 15 August 2022).
  112. Yeung, E.H.; Zhang, C.; Mumford, S.L.; Ye, A.; Trevisan, M.; Chen, L.; Browne, R.W.; Wactawski-Wende, J.; Schisterman, E.F. Longitudinal Study of Insulin Resistance and Sex Hormones over the Menstrual Cycle: The Biocycle Study. J. Clin. Endocrinol. Metab. 2010, 95, 5435–5442. [Google Scholar] [CrossRef] [PubMed]
  113. Di Pierro, F.; Callegari, A.; Carotenuto, D.; Tapia, M.M. Clinical Efficacy, Safety and Tolerability of BIO-C (Micronized Silymarin) as a Galactagogue. Acta Biomed. 2008, 79, 205–210. [Google Scholar]
  114. Kelly, G.S. Insulin Resistance: Lifestyle and Nutritional Interventions. Altern. Med. Rev. 2000, 5, 109–132. [Google Scholar]
  115. Li, M.; Chi, X.; Wang, Y.; Setrerrahmane, S.; Xie, W.; Xu, H. Trends in Insulin Resistance: Insights into Mechanisms and Therapeutic Strategy. Signal Transduct. Target. Ther. 2022, 7, 216. [Google Scholar] [CrossRef] [PubMed]
  116. Wolosowicz, M.; Prokopiuk, S.; Kaminski, T.W. Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle? Medicina 2022, 58, 472. [Google Scholar] [CrossRef] [PubMed]
  117. Almeda-Valdés, P.; Bello-Chavolla, O.Y.; Caballeros-Barragán, C.R.; Gómez-Velasco, D.V.; Viveros-Ruiz, T.; Vargas-Vázquez, A.; Aguilar-Salinas, C.A. Índices Para La Evaluación de La Resistencia a La Insulina En Individuos Mexicanos Sin Diabetes. Gac. Méx. 2018, 154, S50–S55. [Google Scholar] [CrossRef]
  118. Bello-Chavolla, O.Y.; Almeda-Valdes, P.; Gomez-Velasco, D.; Viveros-Ruiz, T.; Cruz-Bautista, I.; Romo-Romo, A.; Sánchez-Lázaro, D.; Meza-Oviedo, D.; Vargas-Vázquez, A.; Campos, O.A.; et al. METS-IR, a Novel Score to Evaluate Insulin Sensitivity, Is Predictive of Visceral Adiposity and Incident Type 2 Diabetes. Eur. J. Endocrinol. 2018, 178, 533–544. [Google Scholar] [CrossRef] [PubMed]
  119. Reyes-Muñoz, E.; Martínez-Herrera, E.M.; Ortega-González, C.; Arce-Sánchez, L.; Ávila-Carrasco, A.; Zamora-Escudero, R. Valores de Referencia de Homa-Ir y Quicki Durante El Embarazo En Mujeres Mexicanas. Ginecol. Obs. Mex. 2017, 85, 306–313. [Google Scholar]
  120. NEOCHOLAL-S—Medicamento—PR Vademecum. Available online: https://mx.prvademecum.com/medicamento/neocholal-s-14928/ (accessed on 30 May 2020).
  121. Organización Mundial de la Salud. Cuestionario Mundial Sobre Actividad Física; Departamento de enfermedades crónicas y promoción de la salud: Geneva, Switzerland, 2014; p. 3. [Google Scholar]
  122. Hoos, T.; Espinoza, N.; Marshall, S.; Arredondo, E.M. Validity of the Global Physical Activity Questionnaire (GPAQ) in Adult Latinas. J. Phys. Act. Health 2012, 9, 698–705. [Google Scholar] [CrossRef]
  123. Cleland, C.L.; Hunter, R.F.; Kee, F.; Cupples, M.E.; Sallis, J.F.; Tully, M.A. Validity of the Global Physical Activity Questionnaire (GPAQ) in Assessing Levels and Change in Moderate-Vigorous Physical Activity and Sedentary Behaviour. BMC Public Health 2014, 14, 1255. [Google Scholar] [CrossRef] [PubMed]
  124. Lohman, T.; Roch, A.; Martorell, R. Anthropometric Standardization Reference Manual; Human Kinetic Books: Champaign, IL, USA, 1998. [Google Scholar]
Table 1. Anthropometric and body composition characteristics of enrolled patients at baseline and at 12 weeks of silymarin treatment.
Table 1. Anthropometric and body composition characteristics of enrolled patients at baseline and at 12 weeks of silymarin treatment.
ParametersBaseline (n = 6)At 12 Weeks (n = 6)Differencep *
Age (years)34.4 ± 8.6-
Height (cm)159.2 ± 8.4-
Weight (kg)82.9 ± 11.682.9 ± 11.30.020.966
BMI (kg/m2)33.9 ± 2.633.9 ± 2.20.001.000
Wc (cm)91.8 ± 4.792.3 ± 9.90.420.917
Hc (cm)112.7 ± 11.8113.3 ± 8.80.600.843
TBF (%)47.9 ± 1.747.2 ± 1.3−0.770.163
Visc fat (%)9.0 ± 1.48.8 ± 1.6−0.170.363
Lean mass (%)22.8 ± 1.423.4 ± 1.30.550.111
Data are expressed as the mean ± standard deviation and compared using Student’s t-test (n = 6). * p < 0.05 was considered statistically significant. Abbreviations: BMI, body mass index; Wc, waist circumference; Hc, hip circumference; TBF, total body fat; Visc fat: visceral fat.
Table 2. Glucose variation, lipid profile, liver function, inflammation markers of enrolled patients at baseline and at 12 weeks of silymarin treatment.
Table 2. Glucose variation, lipid profile, liver function, inflammation markers of enrolled patients at baseline and at 12 weeks of silymarin treatment.
ParametersBaseline (n = 6)At 12 Weeks (n = 6)Differencep
FPG (mg/dL)96.7 ± 4.291.2 ± 6.8−5.50.041 *
FPI (mcU/mL)14.9 ± 5.212.6 ± 3.8−2.30.159
HOMA-IR 3.6 ± 1.22.8 ± 0.9−0.70.048 *
Hb1Ac (%)5.8 ± 0.35.8 ± 0.400.855
TC (mg/dL)170.3 ± 33.9161.3 ± 24.7−90.393
LDL-C (mg/dL)116.3 ± 28.7110.2 ± 18.5−6.10.554
HDL-C (mg/dL)43.2 ± 8.841.8 ± 5.3−1.40.500
Tg (mg/dL)154.8 ± 47.6145.0 ± 43.5−9.80.198
AST (U/L)19.7 ± 9.121.3 ± 9.51.60.437
ALT (U/L)24.8 ± 21.428.3 ± 23.23.50.461
UA (mg/dL)4.2 ± 0.64.2 ± 0.801.000
TB (mg/dL)0.6 ± 0.10.6 ± 0.200.745
IB (mg/dL)0.5 ± 0.10.5 ± 0.300.727
DB (mg/dL)0.1 ± 00.2 ± 0.10.10.312
CRP (mg/dL)3.4 ± 0.83.3 ± 1.2−0.10.795
Data are expressed as the mean ± standard deviation and compared using Student’s t-test (n = 6). * p < 0.05 was considered statistically significant. Abbreviations: FPG, fasting plasma glucose; FPI, fasting plasma insulin; HOMA-IR, Homeostatic Model of the Insulin Resistance Index; Hb1Ac, glycated hemoglobin; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Tg, triglycerides; AST, aspartate aminotransferase; ALT, alanine aminotransferase; UA, uric acid; TB, total bilirubin; IB, indirect bilirubin; DB, direct bilirubin; CRP, C-reactive protein.
Table 3. Differences in biochemical parameters of enrolled patients at baseline and after silymarin treatment (t = 12 weeks) during the oral glucose tolerance test.
Table 3. Differences in biochemical parameters of enrolled patients at baseline and after silymarin treatment (t = 12 weeks) during the oral glucose tolerance test.
FastingPostprandial
Time (min)0306090120
Glucose (mg/dL)Baseline96.7 ± 4.2147.2 ± 25.5176.2 ± 36.1155.4 ± 30.8147.0 ± 21.5
At 12 weeks91.2 ± 6.8144.6 ± 32.0163.0 ± 15.1146.8 ± 23.4138.6 ± 26.3
Difference5.5−2.6−8.4−4.6−3.8
p0.041 *0.8670.4980.7150.687
Insulin (mcU/mL)Baseline14.9 ± 5.278.9 ± 34.7139.5 ± 68.6111.3 ± 62.6150.1 ± 76.4
At 12 weeks12.6 ± 3.871.6 ± 37.3109.8 ± 40.4130.4 ± 44.1120.9 ± 47.4
Difference−2.3−7.3−29.719.1−29.2
p0.1590.6020.1960.5920.3
Data are expressed as the mean ± standard deviation and compared using Student’s t-test (n = 6). * p < 0.05 was considered statistically significant.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

MacDonald-Ramos, K.; Monroy, A.; Bobadilla-Bravo, M.; Cerbón, M. Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity. Int. J. Mol. Sci. 2024, 25, 2050. https://doi.org/10.3390/ijms25042050

AMA Style

MacDonald-Ramos K, Monroy A, Bobadilla-Bravo M, Cerbón M. Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity. International Journal of Molecular Sciences. 2024; 25(4):2050. https://doi.org/10.3390/ijms25042050

Chicago/Turabian Style

MacDonald-Ramos, Karla, Adriana Monroy, Mariana Bobadilla-Bravo, and Marco Cerbón. 2024. "Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity" International Journal of Molecular Sciences 25, no. 4: 2050. https://doi.org/10.3390/ijms25042050

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop